Compounds > n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and gefitinib

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with gefitinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigues, S; Thim, L; Van Aken, E; Van Bocxlaer, S; Westley, BR	1
Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J	1

Other Studies

2 other study(ies) available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and gefitinib

Article	Year
Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:1 Topics: Allantois; Angiogenesis Inducing Agents; Animals; Capillaries; Cells, Cultured; Chick Embryo; Chorion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Growth Substances; Humans; Isoenzymes; Membrane Proteins; Morphogenesis; Mucins; Muscle Proteins; Neovascularization, Physiologic; Neuropeptides; Nitrobenzenes; Peptides; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Sulfonamides; Trefoil Factor-2; Trefoil Factor-3	2003
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. PloS one, 2013, Volume: 8, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2013

Article

Year

Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:1

Topics: Allantois; Angiogenesis Inducing Agents; Animals; Capillaries; Cells, Cultured; Chick Embryo; Chorion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Growth Substances; Humans; Isoenzymes; Membrane Proteins; Morphogenesis; Mucins; Muscle Proteins; Neovascularization, Physiologic; Neuropeptides; Nitrobenzenes; Peptides; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Sulfonamides; Trefoil Factor-2; Trefoil Factor-3

2003

Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.

PloS one, 2013, Volume: 8, Issue:10

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2013